naion glp-1 Sight Unseen: Glucagon-Like Peptide-1 (GLP-1) Agonism Therapy and Nonarteritic Anterior Ischemic Optic Neuropathy Danny D. | ποΈ Important
Description
Simic G, Babic Leko M, Wray S, Harrington C, Delalle I, Jovanov-Milosevic N, et al
A named legal entity is publicly attributed to the platform
, Cani, P
This study seeks to systematically assess and combine existing human-based findings about skin conditions linked to GLP-1RA therapy
Symptoms are most common during the first few weeks or after dose increases and tend to improve over time
